Colorectal Cancer Screening for Cancer Survivors
The risk of colorectal cancer (CRC) is significant among cancer survivors treated with abdominal radiation therapy (RT). Further, CRC is once of the few cancers for which there is effective screening. Although some expert groups recommend early CRC screening for patients with prior abdominal RT, the effectiveness of early screening is unknown. It is also unknown if radiation-induced CRC passes through a "pre-clinical" phase in which precancerous polyps are detectable and treatable prior to becoming invasive cancers. This study will evaluate whether screening will detect pre-invasive colorectal polyps among survivors treated with RT.
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy|
- The proportion of screened patients with any polyp or any high risk polyp will be calculated. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- Proportion calculation/identification of: demographic/treatment influences on polyp prevalence; subgroups w/polyp prevalence >20%; pts with polyps beyond 30cm flexible sigmoidoscope; pts with adenomatous polyp(s) on colonoscopy in/outside prior RT fields [ Time Frame: 3 years ] [ Designated as safety issue: No ]
|Study Start Date:||May 2008|
|Estimated Study Completion Date:||December 2016|
|Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
All patients enrolled in the study will be undergoing the same procedures.
Other: Colonoscopic examination
All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
Cancer survivors meeting the COG criteria for CRC screening will undergo colonoscopy and removal of colorectal polyps. Documentation of polyp number, location and pathologic characteristics will be made. Clinical data information will also be collected at the time of patient enrollment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00982059
|United States, Massachusetts|
|Dana-Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|University Health Network|
|Toronto, Ontario, Canada, M5G 2M9|
|Principal Investigator:||David Hodgson, MD||University Health Network, Princess Margaret Hospital|
|Principal Investigator:||Andrea K Ng, MD||Dana-Farber Cancer Institute|